攝護腺癌療法第二期臨床試驗正式啟動
New Phase 2 Clinical Trial Begins for Prostate Cancer Therapy
Updated at: July 16, 2026 at 12:15 AM
攝護腺癌的醫學研究在2026年7月中旬達到了新的里程碑，這得益於OPTIMAL-e第二階段臨床試驗的啟動。
Medical research for prostate cancer reached a new milestone in mid-July 2026 with the launch of the OPTIMAL-e Phase 2 clinical trial.
這項研究由Telix Pharmaceuticals和悉尼的聖文森醫院（St Vincent’s Hospital）共同執行，旨在評估一種名為TLX597-Tx的前瞻性新療法。
This study, conducted by Telix Pharmaceuticals and St Vincent’s Hospital in Sydney, evaluates a promising new therapy called TLX597-Tx.
該治療方式採用放射性配體技術，特定標靶PSMA，以治療轉移性荷爾蒙敏感型攝護腺癌男性患者。
This treatment uses radioligand technology, specifically targeting PSMA to treat men with metastatic hormone-sensitive prostate cancer.
此試驗的獨特之處在於其專注於適應性劑量調整，利用先進的影像技術和血液標記物來為每位患者客製化治療計畫。
What makes this trial unique is its focus on adaptive dosing, which uses advanced imaging and blood markers to customize the treatment plan for each patient.
透過在疾病進程的早期進行干預，研究人員希望能提升患者的存活率與生活品質。
By intervening earlier in the disease progression, researchers hope to improve both survival rates and quality of life.
此試驗是全球性龐大研究計畫的一部分，目前有超過1,000項活躍的攝護腺癌研究正在進行。
This trial is part of a larger global effort, with over 1,000 active prostate cancer studies currently underway.
科學家正逐漸擺脫「一體適用」的模式，轉而向精準醫療靠攏。
Scientists are increasingly moving away from a one-size-fits-all model, shifting instead toward precision medicine.
透過結合標靶治療與傳統荷爾蒙治療，目標是提供個人化且有效的照護。
By combining targeted therapies with traditional hormonal treatments, the goal is to provide personalized, effective care.
隨著早期結果顯示其具有良好的安全性檔案，且對非標靶器官（如腎臟）的影響極低，醫學界對PSMA標靶癌症治療的未來仍持樂觀態度。
With early results showing a favorable safety profile and low impact on non-target organs like the kidneys, the medical community remains optimistic about the future of PSMA-targeted cancer treatments.
